These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38082326)

  • 1. Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study-protocol for a phase 3, randomized, controlled trial.
    Snyder EL; Sekela ME; Welsby IJ; Toyoda Y; Alsammak M; Sodha NR; Beaver TM; Pelletier JPR; Gorham JD; McNeil JS; Sniecinski RM; Pearl RG; Nuttall GA; Sarode R; Reece TB; Kaplan A; Davenport RD; Ipe TS; Benharash P; Lopez-Plaza I; Gammon RR; Sadler P; Pitman JP; Liu K; Bentow S; Corash L; Mufti N; Varrone J; Benjamin RJ;
    Trials; 2023 Dec; 24(1):799. PubMed ID: 38082326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Red blood cells treated with the amustaline (S-303) pathogen reduction system: a transfusion study in cardiac surgery.
    Brixner V; Kiessling AH; Madlener K; Müller MM; Leibacher J; Dombos S; Weber I; Pfeiffer HU; Geisen C; Schmidt M; Henschler R; North A; Huang N; Mufti N; Erickson A; Ernst C; Rico S; Benjamin RJ; Corash LM; Seifried E
    Transfusion; 2018 Apr; 58(4):905-916. PubMed ID: 29498049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of natural and acquired antibodies to amustaline/glutathione pathogen reduced red blood cells.
    Geisen C; North A; Becker L; Brixner V; von Goetz M; Corash L; Benjamin RJ; Mufti N; Seifried E
    Transfusion; 2020 Oct; 60(10):2389-2398. PubMed ID: 32692456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients.
    Benjamin RJ; McCullough J; Mintz PD; Snyder E; Spotnitz WD; Rizzo RJ; Wages D; Lin JS; Wood L; Corash L; Conlan MG
    Transfusion; 2005 Nov; 45(11):1739-49. PubMed ID: 16271099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study.
    Cancelas JA; Gottschall JL; Rugg N; Graminske S; Schott MA; North A; Huang N; Mufti N; Erickson A; Rico S; Corash L
    Vox Sang; 2017 Apr; 112(3):210-218. PubMed ID: 28220519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transfusion of red blood cells stored for shorter versus longer duration for all conditions.
    Shah A; Brunskill SJ; Desborough MJ; Doree C; Trivella M; Stanworth SJ
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD010801. PubMed ID: 30578732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits and harms of red blood cell transfusions in patients with septic shock in the intensive care unit.
    Holst LB
    Dan Med J; 2016 Feb; 63(2):. PubMed ID: 26836806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemia.
    Aydinok Y; Piga A; Origa R; Mufti N; Erickson A; North A; Waldhaus K; Ernst C; Lin JS; Huang N; Benjamin RJ; Corash L
    Br J Haematol; 2019 Aug; 186(4):625-636. PubMed ID: 31148155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robust inactivation of Plasmodium falciparum in red blood cell concentrates using amustaline and glutathione pathogen reduction.
    Sow C; Bouissou A; Girard YA; Singh GB; Bounaadja L; Payrat JM; Haas D; Isola H; Lanteri MC; Bringmann P; Grellier P
    Transfusion; 2022 May; 62(5):1073-1083. PubMed ID: 35385146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfusion thresholds for guiding red blood cell transfusion.
    Carson JL; Stanworth SJ; Dennis JA; Trivella M; Roubinian N; Fergusson DA; Triulzi D; Dorée C; Hébert PC
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD002042. PubMed ID: 34932836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non-cardiac surgery.
    Kaufner L; von Heymann C; Henkelmann A; Pace NL; Weibel S; Kranke P; Meerpohl JJ; Gill R
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD012451. PubMed ID: 32790892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients - the study design of the LIBERAL-Trial.
    Meybohm P; Lindau S; Treskatsch S; Francis R; Spies C; Velten M; Wittmann M; Gueresir E; Stoppe C; Kowark A; Coburn M; Selleng S; Baschin M; Jenichen G; Meersch M; Ermert T; Zarbock A; Kranke P; Kredel M; Helf A; Laufenberg-Feldmann R; Ferner M; Wittenmeier E; Gürtler KH; Kienbaum P; de Abreu MG; Sander M; Bauer M; Seyfried T; Gruenewald M; Choorapoikayil S; Mueller MM; Seifried E; Brosteanu O; Bogatsch H; Hasenclever D; Zacharowski K;
    Trials; 2019 Feb; 20(1):101. PubMed ID: 30717805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Number of RBC units and rate of transfusionto anemic HIV-positive patients assigned to receiveWBC-reduced or non-WBC-reduced RBCs: the viral activation transfusion study experience.
    Brecher ME; Triulzi DJ; Assmann SF;
    Transfusion; 2001 Jun; 41(6):794-8. PubMed ID: 11399822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivation of Plasmodium falciparum in whole blood using the amustaline and glutathione pathogen reduction technology.
    Sow C; Laughhunn A; Girard YA; Lanteri MC; Amar El Dusouqui S; Stassinopoulos A; Grellier P
    Transfusion; 2020 Apr; 60(4):799-805. PubMed ID: 32129497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Age of Blood Evaluation (ABLE) randomized controlled trial: study design.
    Lacroix J; Hébert P; Fergusson D; Tinmouth A; Blajchman MA; Callum J; Cook D; Marshall JC; McIntyre L; Turgeon AF;
    Transfus Med Rev; 2011 Jul; 25(3):197-205. PubMed ID: 21550205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.